Search Result

Results for "

Non-covalent

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Apoptosis (8) Arginase (1) AUTACs (1) Autophagy (1) Bacterial (4) Beta-lactamase (1) Btk (10) Cathepsin (1) CDK (7) CRFR (2) CRM1 (3) Dengue virus (1) Deubiquitinase (2) DNA Methyltransferase (3) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) EGFR (4) FAAH (1) Ferroptosis (1) Flavivirus (1) FLT3 (1) Fluorescent Dye (6) Glutathione Peroxidase (1) HCV (2) HCV Protease (3) Histone Demethylase (3) Histone Methyltransferase (2) HIV (1) iGluR (1) Itk (1) Keap1-Nrf2 (3) MAGL (2) Microtubule/Tubulin (1) MNK (1) NEDD8-activating Enzyme (2) NF-κB (1) Notch (2) Parasite (2) Phospholipase (3) PKA (1) Proteasome (1) Protein Arginine Deiminase (1) Ras (4) SARS-CoV (16) STING (2) Virus Protease (4)
By Research Areas:	Cancer (52) Cardiovascular Disease (5) Endocrinology (4) Infection (29) Inflammation/Immunology (10) Metabolic Disease (7) Neurological Disease (6)
Click Chemistry:	Alkynes (1)

108

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136259

ML188 4 Publications Verification	SARS-CoV Virus Protease	Infection
ML188, a first in class probe, is a selective non-covalent SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.5 μM. Antiviral activity .

HY-139535

Luxeptinib CG-806	FLT3 Btk Apoptosis	Cancer
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells .

HY-162321

ZINC57632462	Ras	Cancer
ZINC57632462 (ACA-6) is a non-covalent allosteric KRAS inhibitor. ZINC57632462 disrupts nucleotide exchange and inhibits RAS-effector interaction. ZINC57632462 can be used for the research of cancer .

HY-155143

CDD-1733	SARS-CoV	Infection
CDD-1733 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a K_i of 12 nM. CDD-1733 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants .

HY-155142

CDD-1819	SARS-CoV	Infection
CDD-1819 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a K_i of 5 nM. CDD-1819 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants .

HY-155144

CDD-1845	SARS-CoV	Infection
CDD-1845 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a K_i of 3 nM. CDD-1845 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants .

HY-149929

EBL-3183	Beta-lactamase Bacterial	Infection
EBL-3183, an indole-2-carboxylate, is a potent metallo-β-lactamase (MBL) inhibitor. EBL-3183 is reversibly binding, non-covalent, competitive NDM-1 inhibitor with a pIC₅₀ of 7.7 .

HY-133130

JNJ-42226314	MAGL	Neurological Disease
JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .

HY-156029

IA1-8H2	Others	Cancer
IA1-8H2 is a non-covalent, non-competitive inhibitor of PHPT1 (IC₅₀: 3.4 μM). IA1-8H2 can be used for research of lung cancer, hepatocarcinoma, and renal cancer .

HY-114299

Salcaprozate sodium SNAC	Others	Others
Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation .

HY-144369

Proteasome-IN-4	Proteasome	Cancer
Proteasome-IN-4 is an excellent and non-covalent proteasome inhibitor (IC₅₀=8.39 nM). Proteasome-IN-4 has potent antiproliferative activities against RPMI-8226, MM-1S and MV-4-11 cell lines. Proteasome-IN-4 can be used for cancer research .

HY-101790

ZM223

NEDD8-activating Enzyme Cancer

ZM223 is a potent non-covalent NEDD8 activating enzyme (NAE) inhibitor, orally active .

ZM223	NEDD8-activating Enzyme	Cancer
ZM223 is a potent non-covalent NEDD8 activating enzyme (NAE) inhibitor, orally active .

HY-157145

SARS-CoV-2-IN-69	SARS-CoV	Infection
SARS-CoV-2-IN-69 (Compound 7E) is a non-covalent SARS-CoV-2 inhibitor with an EC₅₀ value of 7.4 μM. SARS-CoV-2-IN-69 is a potent inhibitor of SARS-CoV-2 main protease (M ^pro) and a non-covalent inhibitor of papain (PL ^pro) .

HY-155186

SARS-CoV-2 3CLpro-IN-19	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC₅₀ values between 30-69 nM .

HY-101790A

ZM223 hydrochloride	NEDD8-activating Enzyme	Cancer
ZM223 hydrochloride is an orally active, potent non-covalent NEDD8 activating enzyme (NAE) inhibitor with excellent anticancer activity .

HY-10243

Vaniprevir

MK-7009
HCV HCV Protease Infection

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.
HY-19415

SB-435495

Phospholipase Metabolic Disease

SB-435495 is a potent, selective, reversible, non-covalent and orally active Lp-PLA₂ inhibitor with an IC₅₀ of 0.06 nM .

Vaniprevir MK-7009	HCV HCV Protease	Infection
Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

SB-435495	Phospholipase	Metabolic Disease
SB-435495 is a potent, selective, reversible, non-covalent and orally active Lp-PLA₂ inhibitor with an IC₅₀ of 0.06 nM .

HY-19415A

SB-435495 hydrochloride	Phospholipase	Metabolic Disease
SB-435495 hydrochloride is a potent, selective, reversible, non-covalent and orally active Lp-PLA₂ inhibitor with an IC₅₀ of 0.06 nM .

HY-19415B

SB-435495 ditartrate	Phospholipase	Metabolic Disease
SB-435495 ditartrate is a potent, selective, reversible, non-covalent and orally active Lp-PLA₂ inhibitor with an IC₅₀ of 0.06 nM .

HY-143216

Ensitrelvir 5+ Cited Publications S-217622	SARS-CoV Virus Protease	Infection
Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC₅₀=13 nM) .

HY-143216A

Ensitrelvir fumarate 5+ Cited Publications S-217622 fumarate	SARS-CoV Virus Protease	Infection
Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC₅₀=13 nM) .

HY-136430

JCN037 JGK037	EGFR	Cancer
JCN037 (JGK037) is non-covalent and BBB-penetrant EGFR tyrosine kinase inhibitor, with IC₅₀ values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively .

HY-132882

ARN19689	Others	Inflammation/Immunology
ARN19689 is a potent, selective, orally active and non-covalent inhibitor of N‑Acylethanolamine-Hydrolyzing Acid Amidase (NAAA), with an IC₅₀ of 42 nM. ARN19689 is a promising pharmacological tool to be further investigated in the field of inflammatory conditions .

HY-131328A

(R)-Pirtobrutinib (R)-LOXO-305	Btk	Others
(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations .

HY-134184

AUTAC2	AUTACs Autophagy	Inflammation/Immunology Cancer
AUTAC2 is a FKBP12-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG (p-Fluorobenzyl Guanine) and an SLF (c ligand of FKBP) moiety. SLF binds non-covalently to FKBP12 .

HY-103462

TC-F2	FAAH	Metabolic Disease Inflammation/Immunology Cancer
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .

HY-146068

AEP-IN-1	Others	Neurological Disease
AEP-IN-1 (Compound 13e) is a CNS agent-like non-covalent inhibitor of asparagine endopeptidase (AEP), with the IC₅₀ of 89 nM. AEP-IN-1 can be used for the research of numerous neurological diseases such as Alzheimer’s disease (AD) .

HY-112215

Nemtabrutinib 1 Publications Verification ARQ-531; MK-1026	Btk	Inflammation/Immunology Cancer
ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase (BTK), with IC₅₀s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.

HY-136298A

X77

SARS-CoV Infection

X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (SARS-CoV-2 M ^pro) . X77 binds to SARS-CoV-2 M ^pro with a K_d value of 0.057 μM .

X77	SARS-CoV	Infection
X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (SARS-CoV-2 M ^pro) . X77 binds to SARS-CoV-2 M ^pro with a K_d value of 0.057 μM .

HY-135146

GSK-3484862 5+ Cited Publications	DNA Methyltransferase	Cancer
GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1). GSK-3484862 induces DNA hypomethylation to against cancer. GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicity .

HY-153450

JBI-589	Protein Arginine Deiminase	Cancer
JBI-589 is a non-covalent PAD4 isoform-selective inhibitor. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors .

HY-136531

XMU-MP-3	Btk Apoptosis	Cancer
XMU-MP-3 is a potent non-covalent BTK inhibitor with IC₅₀s of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation in the presence of 10 μM ATP, respectively. XMU-MP-3 also induces apoptosis .

HY-141514

MSA-2 dimer 1 Publications Verification	STING	Inflammation/Immunology Cancer
MSA-2 dimer is a selective, orally active non-nucleotide STING agonist (K_d=145 μM) with long-term antitumor and immunogenic activity. MSA-2 dimer is bound to STING as a non-covalent dimer exhibiting higher permeability than cyclic dinucleotide .

HY-160168

BTK-IN-31	Btk	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .

HY-122723

GOT1 inhibitor-1 1 Publications Verification	Others	Cancer
GOT1 inhibitor-1 (compound 2c), a tryptamine-based derivative, acts as a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC₅₀ of 8.2 uM. GOT1 inhibitor-1 can be used for the research of pancreatic ductal adenocarcinoma (PDAC) .

HY-136298

(Rac)-X77	SARS-CoV	Infection
(Rac)-X77 is a racemate of X77. X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (SARS-CoV-2 M ^pro) . X77 binds to SARS-CoV-2 M ^pro with a K_d value of 0.057 μM .

HY-156004

Ziapin 2	Others	Others
Ziapin 2 is a molecular optomechanical light transducer. Ziapin 2 is an amphiphilic azobenzene with a strong non-covalent affinity to the plasma membrane. Ziapin 2 can be used to photo-modulate the membrane potential in cells of the Gram-positive bacterium Bacillus subtilis. Ziapin 2 enters the lipid membrane very rapidly (≈ 40 ns) .

HY-149535

WU-04	SARS-CoV	Infection
WU-04 is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein. WU-04 has high inhibitory effect on the 3CLpro protein of 6 SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Lambda and Omicron) and 2 coronaviruses (SARS-CoV and MERS-CoV) .

HY-117203A

CDK12-IN-E9	CDK	Cancer
CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC₅₀> 1 μM .

HY-112937

GNE-6640 2 Publications Verification	Deubiquitinase	Cancer
GNE-6640 is a selective and non-covalent inhibitor of ubiquitin epecific peptidase 7 (USP7), with IC₅₀ values of 0.75 μM, 0.43 μM, 20.3 μM and 0.23 μM for full length USP7, USP7 catalytic domain, full length USP43 and Ub-MDM2, respectively .

HY-135146A

(Rac)-GSK-3484862	Others	Cancer
(Rac)-GSK-3484862 is the isomer of GSK-3484862 (HY-135146), and can be used as an experimental control. GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1). GSK-3484862 induces DNA hypomethylation to against cancer. GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicity .

HY-134205A

CBR-470-1 1 Publications Verification	Keap1-Nrf2	Neurological Disease Metabolic Disease
CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1). CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP ⁺-induced cytotoxicity through activation of the Keap1-Nrf2 cascade .

HY-129589

Thailanstatin A	ADC Cytotoxin	Cancer
Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC₅₀=650 nM). Thailanstatin A exerts effects via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome and shows low-nM to sub-nM IC₅₀s against multiple cancer cell lines. Thailanstatin A, a payload for ADCs, is conjugated to the lysines on trastuzumab yielding “linker-less” ADC .

HY-146283

LSD1-IN-18	Histone Demethylase	Cancer
LSD1-IN-18 (compound 7) is a potent, non-covalent and selective LSD1 inhibitor, with K_i of 0.156 μM and K_D of 0.075 μM, respectively. LSD1-IN-18 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.16 and 0.21 μM, respectively .

HY-146284

LSD1-IN-19	Histone Demethylase	Cancer
LSD1-IN-19 (compound 29) is a potent, non-covalent and selective LSD1 inhibitor, with K_i of 0.108 μM and K_D of 0.068 μM, respectively. LSD1-IN-19 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.17 and 0.40 μM, respectively .

HY-150702

MAGLi 432	MAGL	Neurological Disease Inflammation/Immunology
MAGLi 432 is a non-covalent, potent, highly selective, and reversible MAGL inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC₅₀ values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease .

HY-131328

Pirtobrutinib 1 Publications Verification LOXO-305	Btk	Cancer
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM .

HY-151482

SARS-CoV-2 Mpro-IN-2	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-2 (compound GC-14) is a selective, low cytotoxic and non-covalent M ^pro inhibitor (IC₅₀=0.40 μM) with good anti-SARS-CoV-2 activity (EC₅₀=1.1 μM). SARS-CoV-2 Mpro-IN-2 can be used in COVID-19 studies .

HY-106991A

Amustaline dihydrochloride S-303 dihydrochloride	HIV Bacterial	Infection
Amustaline (S-303) dihydrochloride, a nucleic acid-targeted alkylator, is an efficient pathogen inactivation agent for blood components containing red blood cells. Amustaline dihydrochloride has three components: an acridine anchor (an intercalator that targets nucleic acids non-covalently), an effector (a bis-alkylator group that reacts with nucleophiles), and a linker (a small flexible carbon chain containing a labile ester bond that hydrolyzes at neutral pH to yield non-reactive breakdown products) .

HY-146285

LSD1-IN-20	Histone Demethylase Histone Methyltransferase	Cancer
LSD1-IN-20 (compound 1) is a potent dual non-covalent LSD1/G9a inhibitor, with K_i values of 0.44 and 0.68 μM, respectively. LSD1-IN-20 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.51 and 1.60 μM, respectively .

Cat. No.	Product Name

HY-L036

Covalent Screening Library

1670 compounds

Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery.

MCE covalent inhibitor library contains 1670 small molecules including identified covalent inhibitors and other bioactive molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, Sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

HY-L036P

Covalent Screening Library Plus

2988 compounds

MCE covalent inhibitor library contains 2988 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Cat. No.	Product Name	Type

HY-D1804

Vari Fluor 680-Streptavidin

Dyes

Vari Fluor 680-Streptavidin is a dye marker of Vari Fluor-streptavidin consisting of labeling streptavidin with a Vari Fluor series of fluorescent probes. Streptavidin is a high-affinity tetramer protein, each tetramer consisting of four identical streptavidin subunits. Streptavidin binds to biotin specifically via a reversible non-covalent effect. Streptavidin can achieve rapid and efficient detection of biotin markers, and is often used in immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining (IFH), in situ hybridization (ISH) and other experiments. Ex/Em=680 nm/701 nm.

HY-D1805

Vari Fluor 647-Streptavidin

Dyes

Vari Fluor 647-Streptavidin is a dye marker of Vari Fluor-streptavidin consisting of labeling streptavidin with a Vari Fluor series of fluorescent probes. Streptavidin is a high-affinity tetramer protein, each tetramer consisting of four identical streptavidin subunits. Streptavidin binds to biotin specifically via a reversible non-covalent effect. Streptavidin can achieve rapid and efficient detection of biotin markers, and is often used in immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining (IFH), in situ hybridization (ISH) and other experiments. Ex/Em=650 nm/665 nm.

HY-D1806

Vari Fluor 594-Streptavidin

Dyes

Vari Fluor 594-Streptavidin is a dye marker of Vari Fluor-streptavidin consisting of labeling streptavidin with a Vari Fluor series of fluorescent probes. Streptavidin is a high-affinity tetramer protein, each tetramer consisting of four identical streptavidin subunits. Streptavidin binds to biotin specifically via a reversible non-covalent effect. Streptavidin can achieve rapid and efficient detection of biotin markers, and is often used in immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining (IFH), in situ hybridization (ISH) and other experiments. Ex/Em=590 nm/617 nm.

HY-D1807

Vari Fluor 555-Streptavidin

Dyes

Vari Fluor 555-Streptavidin is a dye marker of Vari Fluor-streptavidin consisting of labeling streptavidin with a Vari Fluor series of fluorescent probes. Streptavidin is a high-affinity tetramer protein, each tetramer consisting of four identical streptavidin subunits. Streptavidin binds to biotin specifically via a reversible non-covalent effect. Streptavidin can achieve rapid and efficient detection of biotin markers, and is often used in immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining (IFH), in situ hybridization (ISH) and other experiments. Ex/Em=555 nm/565 nm.

HY-D1808

Vari Fluor 488-Streptavidin

Dyes

Vari Fluor 488-Streptavidin is a dye marker of Vari Fluor-streptavidin consisting of labeling streptavidin with a Vari Fluor series of fluorescent probes. Streptavidin is a high-affinity tetramer protein, each tetramer consisting of four identical streptavidin subunits. Streptavidin binds to biotin specifically via a reversible non-covalent effect. Streptavidin can achieve rapid and efficient detection of biotin markers, and is often used in immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining (IFH), in situ hybridization (ISH) and other experiments. Ex/Em=490 nm/515 nm.

HY-D1809

Vari Fluor 405-Streptavidin

Dyes

Vari Fluor 405-Streptavidin is a dye marker of Vari Fluor-streptavidin consisting of labeling streptavidin with a Vari Fluor series of fluorescent probes. Streptavidin is a high-affinity tetramer protein, each tetramer consisting of four identical streptavidin subunits. Streptavidin binds to biotin specifically via a reversible non-covalent effect. Streptavidin can achieve rapid and efficient detection of biotin markers, and is often used in immunofluorescence (IF), enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining (IFH), in situ hybridization (ISH) and other experiments. Ex/Em=405 nm/431 nm.

Cat. No.	Product Name	Target	Research Area

HY-P2265A

SAH-SOS1A TFA	Ras	Cancer
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P10188

apoB (4372-4392)	Peptides	Cardiovascular Disease
apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC₅₀ of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity .

HY-P2203A

SAHM1 TFA	Notch
SAHM1 TFA is a Notch pathway inhibitor. SAHM1 TFA stabilizes hydrocarbon-stapled alpha helical peptide. SAHM1 TFA targets the protein-protein interface and prevents Notch complex assembly.

HY-P2265

SAH-SOS1A	Ras	Cancer
SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC₅₀=106-175 nM), directly and independently blocks nucleotide association, impairs KRAS-driven cancer cell viability, and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS .

HY-P10212

AVLX-125 UCCB01-125	iGluR	Neurological Disease
AVLX-125 (UCCB01-125) is a PSD-95 and PDZ domain inhibitor with K_d value of 10 nM. AVLX-125 can be used in the study of inflammatory pain .

HY-P2261

STAD 2	PKA	Infection
STAD 2 is a potent and selective disruptor of PKA-RII, with a K_d of 6.2 nM. STAD 2 disrupts interactions between PKA and AKAP in an isoform-selective manner. STAD 2 displays antimalarial activity through a PKA-independent mechanism .

HY-N9526

Lyciumin B

Peptides Cardiovascular Disease

Lyciumin B is a cyclic peptide isolated from Lysium chinense .

HY-P2203

SAHM1 1 Publications Verification	Notch	Inflammation/Immunology
SAHM1, a peptide mimetic of a dominant negative form of mastermind-like (MAML), inhibits canonical Notch transcription complex formation. SAHM1 can be used for the research of allergic airway inflammation in mice .

HY-P1368

Stressin I Cyclo(31-34)[DPhe12,Nle21,38,Glu31,Lys34]Ac-hCRF(4-41)	CRFR	Endocrinology
Stressin I (Cyclo(31-34)[DPhe12,Nle21,38,Glu31,Lys34]Ac-hCRF(4-41)) is a potent CRF1 receptor-selective agonist with a K_i of 1.7 nM. Stressin I induces increases in adrenocorticotropic hormone (ACTH) levels in rats .

HY-P1368A

Stressin I TFA Cyclo(31-34)[DPhe12,Nle21,38,Glu31,Lys34]Ac-hCRF(4-41) TFA	CRFR	Endocrinology
Stressin I (Cyclo(31-34)[DPhe12,Nle21,38,Glu31,Lys34]Ac-hCRF(4-41)) TFA is a potent CRF1 receptor selective agonist, K_i is 1.7 nM. Stressin I induces an increase in adrenocorticotropic hormone (ACTH) levels in rats .

HY-P2266

SAH-EZH2	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 .

HY-P10014

Bibapcitide

Peptides Cardiovascular Disease

Bibapcitide, a 26 amino acid, inhibits thrombosis .

HY-P10016

Pegmolesatide HS-20039; EPO-018B	Peptides	Endocrinology
Pegmolesatide(HS-20039; EPO-018B) a synthetic peptide-based erythropoiesis-stimulating agent, can be used for ??the study of anemia in chronic kidney disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Non-covalent

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Click Chemistry

Natural
Products